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Antipsychotic drugs and
metabolic syndrome –
can we prevent it?
Drogas antipsicóticas e
a síndrome metabólica –
podemos evitá-la?
The use of first-and second-generation antipsychotic drugs led
to an unequivocal improvement in the medical treatment of serious
mental illnesses, such as schizophrenia. However, treatment with
these drugs is associated with important side effects such as obesity,
impaired glucose metabolism, dyslipidemia, arterial hypertension,
all of them being phenotypes related with insulin resistance and
collectively termed metabolic syndrome (MS). This syndrome, which
affects one-quarter of the American population, may have serious
consequences for cardiovascular disease (CVD) and diabetes
development. Furthermore, epidemiological studies demonstrated
that the MS is highly prevalent among treated patients with
schizophrenia.1 The reasons for this association between
antipsychotics drugs and MS remains unclear but the alteration in
food intake, reduction in physical activity and direct or indirect
effects in mechanisms of insulin action and/or secretion may be
implicated. The study of Assunção et al. demonstrated that the use
of olanzapine with nizatidine was not effective in controlling weight
gain in patients with schizophrenia.2 Patients had a mean weight
gain of ~12% from baseline randomization to endpoint after 12
weeks. These results reinforce the concept that behavioral
modification, such as physical activity, which promotes a
tremendous effect in the protection against metabolic disturbances
(e.g. diabetes and obesity), probably should be the treatment of
choice for these patients. Indeed, all components of the metabolic
syndrome are improved by even modest amounts of weight loss
achieved with diet and exercise.
The paper of Leitão-Azevedo et al. found an increased rate of
dyslipidemia in schizophrenic patients using some new generation
antipsychotics, mainly lower HDL-cholesterol levels.3 Furthermore,
this study found a very high prevalence of prediabetes (~40%) by
using the last American Diabetes Association cut-off for the diagnosis
of diabetes and prediabetes (ADA-2003). However, the proposed
revised diagnostic criteria are not free of criticism. The adoption of
these criteria will lead to a dramatic increase in the prevalence of
impaired fasting glucose. It is true that these new criteria can
identify subjects with real risk of developing diabetes in the future
but, at the same time, lead to a pandemic of prediabetes. About
25-40% of the adults around the world will have prediabetes.4
This seriously challenges whether the existing intervention strategies
to prevent diabetes (physical activity, weight loss, and the use of
metformin) are applicable to the new category of individuals with
impaired fasting glycemia.
Because of the close associations between obesity, diabetes,
and dyslipidemia with CVD, a recent Consensus was made on
Antipsychotic Drugs and Obesity and Diabetes, with the
participation of representatives of the American Diabetes
Association and American Psychiatric Association among others.5
The panel recommended that baseline screening measures should
be obtained before, or as soon as clinically feasible after, the
initiation of any antipsychotic medication. These include: Personal
and family history of obesity and diabetes, dyslipidemia,
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hypertension, or cardiovascular disease. Weight and height (so
that Body Mass Index can be calculated; waist circumference),
blood pressure, fasting plasma glucose and lipid profile. Fasting
plasma glucose, lipid levels, and blood pressure should also be
assessed 3 months after initiation of antipsychotic medications.
Thereafter, blood pressure and plasma glucose values should be
obtained annually or more frequently in those who have a higher
baseline risk for the development of diabetes or hypertension. In
those with a normal lipid profile, testing should be performed at
5-year intervals or more frequently if clinically indicated.
In conclusion, collaboration between the psychiatric and
diabetology or endocrinologist teams is essential to minimize the
risk of diabetes, obesity and other co-morbidities in patients taking
second-generation antipsychotic medications and for effective
management when it develops. This population, which already
has a high burden of physical morbidity and excess mortality,
should be peremptorily closely monitored, offered appropriate
screening and, where necessary, treatment and perhaps
prevention of these conditions. This collaboration will help
minimize the already high risk of cardiovascular disease in
individuals with schizophrenia and other major mental health
disorders. The question if we can prevent MS in patients using
antipsychotic drugs remains unanswered but a large body of data
suggests that weight loss achieved with diet and exercise could
be the most effective way to promote wealth quality, protecting
against these metabolic dysfunctions.
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